NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Shanxi Qianyecao Biotech QYC

Published 12 Nov 2026. 35-page investigative report on who is behind Shanxi Qianyecao Biotech QYC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 132 Finnrick lab tests, QYC’s record is 89 pass / 43 fail, for an overall pass rate of 67%. This is an uneven and methodology-sensitive catalog: GHK-Cu and Tirzepatide are the comparatively stronger lanes, Retatrutide needs exact-lot confirmation, and BPC-157 carries the sharpest historical identity and fill concern.

The non-lab file is more concerning than an ordinary gray-market profile. Registry data shows the named PRC company as cancelled, while the 2026 sales identity continued under QYC/Amy-QYC channels. The registry owner is identifiable, but the person or entity controlling 2026 trade remains unresolved.

Public verification also degraded. The canonical domain returned an application-level 404, forum posting stopped, old Discord invites were dead or expired, and payment options shifted away from PayPal toward lower-recourse rails. That combination makes new solicitations hard to authenticate and leaves weak leverage if a shipment, label or fill claim fails.

The manufacturing evidence does not close the gap. QYC-origin Janoshik COAs republished through a downstream reseller list Batch Unknown, and one Retatrutide COA notes an unknown presumed filler polymer. No public factory licence, GMP record, named batch-release authority or live lot-verification system surfaced in the reviewed sources.

Inside the full report:

  • Product-specific Finnrick pass/fail analysis and methodology-divergence charts for all 11 tested products
  • Registry, WHOIS and timeline evidence for QYC’s formation, cancellation and channel collapse
  • COA-traceability review of QYC-origin Janoshik reports republished by Revivix Labs
  • Channel-authentication and payment-recourse analysis covering domain, email, Discord, forum and platform rails
  • Network review separating downstream reseller evidence from unproven ownership or hosting-proximity leads

Risk assessment

  • Legal-counterparty and control-opacity risk — high: Named PRC entity 山西千叶草生物科技有限公司 is cancelled, and the 2026 operating vendor or successor controller is not identified.
  • Channel-continuity and vendor-disappearance risk — high: qianyecao.cn returned 404, Peptigrity recorded no response since 2026-11-03, forum posting stopped, and all 14 tested Discord invites were dead or expired.
  • High-failure product-lane risk — high: NAD+, Cagrilintide, BPC-157, TB-500 and Sermorelin are the main affected products; BPC-157 also has field records of zero-active batches.
  • Manufacturing, sterility and batch-traceability risk — high: No public factory/GMP or batch-release evidence surfaced; QYC-origin COAs list Batch Unknown and one Retatrutide COA notes an unknown presumed filler polymer.
  • Copycat and brand-verification risk — medium: QYC has documented impersonation/scam warnings and lacks a live canonical site, authorized-reseller list, serialized checker or signed batch-lookup controls.
  • Payment and buyer-recourse risk — medium: PayPal was shut down and QYC shifted toward bank transfer, Western Union, crypto and platform rails without a verified active legal counterparty.
  • Broad chemical and controlled-product exposure risk — medium: QYC marketed steroid oils/tablets before stopping shipments and its LookChem storefront lists precursor or industrial chemicals under the same QYC identity.